{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:28:36Z","timestamp":1761514116277,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,2]],"date-time":"2020-02-02T00:00:00Z","timestamp":1580601600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jvs.2017.09.026","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T18:52:01Z","timestamp":1513018321000},"page":"656-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia"],"prefix":"10.1016","volume":"67","author":[{"given":"Joep G.J.","family":"Wijnand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Teraa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Gremmels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Femke C.C.","family":"van Rhijn-Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert J.","family":"de Borst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne C.","family":"Verhaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl S","key":"10.1016\/j.jvs.2017.09.026_bib1","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgren","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib2","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","article-title":"Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial","volume":"366","author":"Adam","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2017.09.026_bib3","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jvs.2015.07.065","article-title":"The natural history of untreated severe or critical limb ischemia","volume":"62","author":"Abu Dabrh","year":"2015","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jvs.2010.04.057","article-title":"Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment","volume":"52","author":"Sprengers","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib5","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2337\/diacare.24.10.1799","article-title":"Functional status of persons with diabetes-related lower-extremity amputations","volume":"24","author":"Peters","year":"2001","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.jvs.2017.09.026_bib6","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S1078-5884(11)60009-9","article-title":"Chapter I: definitions, epidemiology, clinical presentation and prognosis","volume":"42","author":"Becker","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib7","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jvs.2011.06.118","article-title":"Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia","volume":"54","author":"Iafrati","year":"2011","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.114.012913","volume":"131","author":"Teraa","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2017.09.026_bib9","article-title":"Environmental influences on endothelial to mesenchymal transition in developing implanted cardiovascular tissue-engineered grafts","author":"Muylaert","year":"2015","journal-title":"Tissue Eng Part B Rev"},{"key":"10.1016\/j.jvs.2017.09.026_bib10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/01.RES.0000118601.37875.AC","article-title":"Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in\u00a0vitro and in\u00a0vivo arteriogenesis through paracrine mechanisms","volume":"94","author":"Kinnaird","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.jvs.2017.09.026_bib11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/SLA.0b013e3182854cf1","article-title":"Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials","volume":"258","author":"Teraa","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib12","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.ejvs.2015.08.018","article-title":"Bone marrow derived cell therapy in critical limb ischemia: a meta-analysis of randomized placebo controlled trials","volume":"50","author":"Peeters Weem","year":"2015","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1479-5876-11-143","article-title":"A\u00a0double blind randomized placebo controlled phase I\/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia","volume":"11","author":"Gupta","year":"2013","journal-title":"J\u00a0Transl Med"},{"key":"10.1016\/j.jvs.2017.09.026_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.diabres.2010.12.010","article-title":"Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial","volume":"92","author":"Lu","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jvs.2017.09.026_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/scrt351","article-title":"Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective","volume":"4","author":"Gremmels","year":"2013","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.jvs.2017.09.026_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5966\/sctm.2016-0237","article-title":"Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger's disease: phase II study report suggests clinical efficacy","volume":"6","author":"Gupta","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jvs.2017.09.026_bib17","doi-asserted-by":"crossref","first-page":"H1888","DOI":"10.1152\/ajpheart.00186.2009","article-title":"Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen","volume":"296","author":"Shabbir","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jvs.2017.09.026_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","article-title":"Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6","volume":"5","author":"Lee","year":"2009","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jvs.2017.09.026_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.transproceed.2006.12.019","article-title":"Stem cell transplantation: the lung barrier","volume":"39","author":"Schrepfer","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jvs.2017.09.026_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.nucmedbio.2011.03.008","article-title":"In\u00a0vivo tracking of 111In-oxine labeled mesenchymal stem cells following infusion in patients with advanced cirrhosis","volume":"38","author":"Gholamrezanezhad","year":"2011","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.jvs.2017.09.026_bib21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbmt.2008.03.012","article-title":"Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease","volume":"15","author":"Kebriaei","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jvs.2017.09.026_bib22","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.athoracsur.2008.11.057","article-title":"Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage","volume":"87","author":"Hamamoto","year":"2009","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtcvs.2011.08.053","article-title":"Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product","volume":"144","author":"Lasala","year":"2012","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jvs.2017.09.026_bib24","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2017.09.026_bib25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.gastro.2015.06.014","article-title":"Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease","volume":"149","author":"Molendijk","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvs.2017.09.026_bib26","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2014.161","article-title":"Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls","volume":"22","author":"Gremmels","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jvs.2017.09.026_bib27","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2017.09.026_bib28","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.jacc.2009.06.055","article-title":"A\u00a0randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction","volume":"54","author":"Hare","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2017.09.026_bib29","doi-asserted-by":"crossref","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.jvs.2017.09.026_bib30","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jvs.2017.09.026_bib31","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1634\/stemcells.2005-0365","article-title":"Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model","volume":"24","author":"Kim","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.jvs.2017.09.026_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/rej.2009.0872","article-title":"Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells","volume":"12","author":"Dash","year":"2009","journal-title":"Rejuvenation Res"},{"key":"10.1016\/j.jvs.2017.09.026_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.carrev.2010.01.001","article-title":"Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study","volume":"12","author":"Lasala","year":"2011","journal-title":"Cardiovasc Revasc Med"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521417323716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521417323716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:20:51Z","timestamp":1760041251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521417323716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0741521417323716"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2017.09.026","relation":{},"ISSN":["0741-5214"],"issn-type":[{"type":"print","value":"0741-5214"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2017.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the Society for Vascular Surgery. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}